Management of Post-Liver Transplant Recurrence of Hepatitis C

Area of Science:

• Hepatology
• Virology
• Transplantation Immunology

Background:

• Chronic hepatitis C (HCV) is a primary reason for liver transplants in North America and Europe.
• HCV recurrence post-transplant is common and compromises patient and graft survival.
• Previous interferon (IFN)-based treatments for HCV had low efficacy and poor tolerability in transplant recipients.

Purpose of the Study:

• To evaluate the efficacy and safety of novel directly acting antivirals (DAAs) for treating HCV recurrence in liver transplant patients.
• To assess the impact of DAA therapy on patient and graft survival post-liver transplantation.

Main Methods:

• Review of clinical trials and real-world studies on DAA therapy for post-transplant HCV.
• Analysis of sustained viral response (SVR) rates, safety profiles, and tolerability of DAA regimens.
• Comparison of DAA outcomes with historical interferon-based treatments.

Main Results:

• DAAs demonstrate high SVR rates in liver transplant recipients with recurrent HCV.
• Interferon-free DAA therapies exhibit favorable safety and tolerability profiles.
• DAAs offer improved outcomes compared to older IFN-based treatments, with fewer drug-drug interactions.

Conclusions:

• Directly acting antivirals represent a breakthrough in managing HCV recurrence after liver transplantation.
• DAA therapy provides an effective, safe, and well-tolerated treatment option, improving outcomes for transplant recipients.
• The advent of DAAs has transformed the treatment landscape for post-liver transplant HCV.